Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totaling 138,763 shares, a growth of 21.8% from the March 31st total of 113,910 shares. Based on an average daily volume of 83,076 shares, the days-to-cover ratio is currently 1.7 days. Approximately 2.6% of the company’s stock are short sold.

Moleculin Biotech Price Performance

Shares of NASDAQ:MBRX opened at $2.51 on Friday. The company has a market capitalization of $13.39 million, a PE ratio of -0.08 and a beta of 1.67. The business has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $5.39. Moleculin Biotech has a 1 year low of $1.79 and a 1 year high of $28.61.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MBRX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moleculin Biotech has an average rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.